Skip to main content

Table 3 Patients’ characteristics

From: Stereotactic body radiotherapy for intramedullary metastases: a retrospective series at the Oscar Lambret center and a systematic review

No. of patients Age (years) Sex WHO* Primary cancer Mutations and Biomarkers Concomitant systemic medication Level Presenting symptoms Muscular strength at diagnosis Use of corticosteroids Time between diagnostic to start of SBRT (days)
1 67 M 2–3 Lung, adenocarcinoma EGFR- / ALK-
PD-L1 70%
No T10 Total paraplegia 0/5 No 14
2 69 F 1 Lung, adenocarcinoma EGFR- / ALK- / KRAS- No T11 Posterior cord syndrome 4/5 No 21
3 72 M 2 Kidney, clear cell carcinoma x No L2 Partial paraplegia 3/5 Yes (1 mg/kg) 6
4 33 M 0 Skin, melanoma x NIVOLUMAB T8 None 5/5 No 33
5 62 F 1 Breast, adenocarcinoma HER +++ / HR + TRASTUZUMAB PERTUZUMAB C4 None 5/5 Yes (1 mg/kg) 44
  1. *World Health Organization (WHO) at the diagnosis of metastasis
  2. Abbreviation: HR: Hormonal Receptors